UAB "Atelda"

COMPANY'S FINANCIAL INFORMATION FOR THE REPORTING PERIOD OF 1 JANUARY 2022 - 30 JUNE 2022

Financial position

| | | | 31 December |
|------|------------------------------------|--------------|-------------|
| | | 30 June 2022 | 2021 |
| | ASSETS | | |
| Α | FIXED ASSETS | - | - |
| I. | Intangible assets | - | - |
| II. | Tangible assets | - | - |
| III. | Financial assets | - | = |
| IV. | Other fixed assets | - | - |
| В | CURRENT ASSETS | 941 | 2 500 |
| ı. | Stocks | - | - |
| II. | Amounts receivable within one year | - | - |
| III. | Short-term investments | - | - |
| IV. | Cash and cash equivalents | 941 | 2 500 |
| С | PREPAYMENTS AND ACCRUED INCOME | | <u> </u> |
| | TOTAL ASSETS | 941 | 2 500 |

Financial position (continued)

| | | | 31 December |
|------|------------------------------------------------------------------|--------------|-------------|
| | | 30 June 2022 | 2021 |
| | EQUITY AND LIABILITIES | | |
| D. | EQUITY | (5 461) | 2 500 |
| ı. | Capital | 2 500 | 2 500 |
| II. | Share premium account | - | - |
| III. | Revaluation reserve | - | - |
| IV. | Reserves | - | = |
| ٧. | Retained profit (loss) | (7 961) | - |
| E. | GRANTS, SUBSIDIES | | - |
| F. | PROVISIONS | | <u>-</u> |
| G. | AMOUNTS PAYABLE AND OTHER LIABILITIES | 4 726 | |
| ı. | Amounts payable after one year and other long-term liabilities | - | - |
| II. | Amounts payable within one year and other short-term liabilities | 4 726 | - |
| н. | ACCRUALS AND DEFERRED INCOME | 1 676 | |
| | TOTAL EQUITY AND LIABILITIES | 941 | 2 500 |

Financial statements signed by electronic signature:

| General Manager | Tomas Milašauskas |
|-------------------------------|---------------------|
| | |
| Representative of a company | |
| providing accounting services | Virginija Skirmantė |

Income Statement

| | | Notes | 2022.01.01 - 2022.06.30 | 2021.01.01 - 2021.06.30 |
|-------|---------------------------------------------------------------------------------------|-------|----------------------------|----------------------------|
| ı. | Net turnover | | - | - |
| II. | Cost of sales | | - | - |
| III. | Fair value adjustments of the biological assets | | - | - |
| IV. | GROSS PROFIT (LOSS) | | - | - |
| ٧. | Selling expenses | | - | - |
| VI. | General and administrative expenses | | (7 961) | - |
| VII. | Other operating results | | - | - |
| VIII. | Income from investments in the shares of parent, subsidiaries and associated entities | | - | - |
| IX. | Income from other long-term investments and loans | | - | - |
| х. | Other interest and similar income | | - | - |
| XI. | The impairment of the financial assets and short-term investments | | - | - |
| XII. | Interest and other similar expenses | | - | - |
| XIII. | PROFIT (LOSS) BEFORE TAXATION | | (7 961) | - |
| XIV. | Tax on profit | | - | - |
| XV. | NET PROFIT (LOSS) | | (7 961) | - |

Financial statements signed by electronic signature:

| General Manager | Tomas Milašauskas |
|-------------------------------|---------------------|
| | |
| Representative of a company | |
| providing accounting services | Virginija Skirmantė |